SLC5A2 and diabetes mellitus: While SGLT-2 inhibitors have also been explored as adjunctive therapies in human patients with type 1 diabetes mellitus [14–16], their use in this population remains cautious due to the potential risk of euglycemic diabetic ketoacidosis.